Starling Oncology, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $6.6M | $-16.0M | $900.0K |
| FY2021 | $0 | $104.2M | $115.2M |
| FY2022 | $80.6M | $123.2M | $14.0M |
| FY2023 | $86.8M | $57.0M | $33.5M |
| FY2024 | $93.1M | $3.6M | $49.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $6.6M | $-16.0M | $900.0K |
| FY2021 | $0 | $104.2M | $115.2M |
| FY2022 | $80.6M | $123.2M | $14.0M |
| FY2023 | $86.8M | $57.0M | $33.5M |
| FY2024 | $93.1M | $3.6M | $49.7M |